Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.Nature Communications|March 15, 2022
DNA methylation-free Arabidopsis reveals crucial roles of DNA methylation in regulating gene expression and developmentLi He, Huan Huang, Mariem Bradai, et al.Computers in Biology and Medicine|February 12, 2021
An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data setYan Liu, Jihui Chen, Yin You, et al.American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.ACS Applied Bio Materials|November 20, 2023
Mechanical Enhancement of the Gelatin/Poly(zinc acrylate) Hydrogel Stent in BileJia-Qi Hu, Jing Wang, Zhen-Hua Shen, et al.Annals of the Rheumatic Diseases|April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.Journal of Materials Chemistry. B|June 25, 2025
An antibacterial hydrogel coating with pH-regulated rifampicin loading for prevention of catheter-associated infectionsJia-Yin You, Jia-Rong Wang, Zhao-Yang Chen, et al.The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.Pageof 3